Istvan Matyas Majer
Istvan Matyas Majer publishes mostly in Economics and Econometrics, Oncology and Hematology, on topics such as Multiple Myeloma Research and Treatments, Rheumatoid Arthritis Research and Therapies and Health Systems, Economic Evaluations, Quality of Life.
- World rank
- #3,481,019 of 7,710,434 ranked researchers
- Rank in Netherlands
- #69,030 of 107,149
- Works
- 89
- Citations
- 888
- Citations per work
- 10.0
What does Istvan Matyas Majer research?
Istvan Matyas Majer's work is mostly in Medicine (37%), Economics, Econometrics and Finance (14%), Biochemistry, Genetics and Molecular Biology (6%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Everything else3842.7%
- Health Sciences3337.1%
- Medicine3337.1%
- Social Sciences1214.0%
- Life Sciences66.2%
- 1Economics and Econometrics14% of their works
- 2Oncology11% of their works
- 3Hematology10% of their works
- 4Rheumatology9% of their works
- 5Pulmonary and Respiratory Medicine7% of their works
- 6Molecular Biology6% of their works
Research topics
- Multiple Myeloma Research and Treatments
- Rheumatoid Arthritis Research and Therapies
- Health Systems, Economic Evaluations, Quality of Life
- Protein Degradation and Inhibitors
- Economic and Financial Impacts of Cancer
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Pharmaceutical Economics and Policy
Which keywords describe Istvan Matyas Majer's research?
The keywords of their largest research topics: Quality of Life, Diagnosis Criteria, International Myeloma Working Group, Inflammation, Rheumatoid Arthritis, Cost-effectiveness Analysis, Health Utility Measures and BET Bromodomains.
- Generic Drugs
- Cetuximab
- Chemotherapy-Induced Peripheral Neuropathy
- Financial Toxicity
- BET Bromodomains
- Cost-effectiveness Analysis
- Inflammation
- Diagnosis Criteria
- Quality of Life
- International Myeloma Working Group
- Rheumatoid Arthritis
- Health Utility Measures
- Cost of Care
- PROTACs
- Taxanes
- Drug Development Costs
- KRAS Mutations
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 17 words, with their numbers
- Quality of Life222 topics
- Diagnosis Criteria211 topic
- International Myeloma Working Group211 topic
- Inflammation151 topic
- Rheumatoid Arthritis151 topic
- Cost-effectiveness Analysis131 topic
- Health Utility Measures131 topic
- BET Bromodomains101 topic
- Cost of Care101 topic
- Financial Toxicity101 topic
- PROTACs101 topic
- Chemotherapy-Induced Peripheral Neuropathy91 topic
- Taxanes91 topic
- Cetuximab81 topic
- Drug Development Costs81 topic
- Generic Drugs81 topic
- KRAS Mutations81 topic
Where does Istvan Matyas Majer work?
Istvan Matyas Majer's main affiliation in the publication record is Pharmerit (Netherlands), Netherlands.
How many publications and citations does Istvan Matyas Majer have?
OpenAlex counts 89 works and 888 citations for Istvan Matyas Majer, an h-index of 15, ranking #3,481,019 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Istvan Matyas Majer. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.